Estrigenix Therapeutics, Inc.

Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company founded in 2018, with its headquarters in the United States. The company's slogan "Improving women’s health through targeted chemistry" encapsulates its focus on developing innovative therapies to address the mental health challenges associated with menopause. Estrigenix's mission is to mitigate the adverse effects of menopause on mental health, aiming to enhance the quality of life for menopausal women. The company's drug development program centers on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. By targeting these receptors, Estrigenix aims to provide cognitive and mood-enhancing benefits without the harmful side effects of standard estrogen therapies. The lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, showing promise in enhancing memory formation in a mouse model of menopause. Furthermore, current efforts are expanding the application of this compound to address additional indications such as depression, anxiety, and hot flashes. Estrigenix's innovative approach addresses a significant unmet need in women's health, particularly in the menopausal demographic. The company's recent investment of $75.00K through a grant, received on 30 May 2023, from the Small Business Innovation Research signifies external validation and support for its endeavors. With a focused vision and promising developments, Estrigenix Therapeutics, Inc. is poised to make meaningful contributions to improving women’s health.